Dr. Villaflor Discusses Alectinib in ALK+ NSCLC

Victoria Villaflor, MD
Published: Wednesday, Oct 04, 2017



Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer (NSCLC).

The ALEX study of alectinib in patients with ALK-positive NSCLC demonstrated a significant benefit in progression-free survival versus standard-of-care crizotinib (Xalkori).
 


Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer (NSCLC).

The ALEX study of alectinib in patients with ALK-positive NSCLC demonstrated a significant benefit in progression-free survival versus standard-of-care crizotinib (Xalkori).
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x